Molecular Devices Partners with Roche
News Nov 06, 2014
The custom technologies arm of Molecular Devices has partnered with the Discovery Technologies team at the Roche Innovation Center Basel of Pharma Research and Early Development (pRED) to develop a high-throughput detection system for drug discovery screens employing Roche’s proprietary Ruthenium-based nanosecond time resolved fluorescence (Nano-TRF®) assays. The pRED screening teams in Basel and Shanghai are now installing the custom-developed Nano-TRF® cartridge in their existing Molecular Devices SpectraMax® Paradigm® multimode microplate readers and will receive on-demand delivery of new cartridges and continuing global technical support.
Nano-TRF® is a robust, Ruthenium-based time-resolved assay used in high-throughput screening for drug discovery. Ruthenium-based dyes combine the advantages of the Lanthanide (e.g. Eu, Tb) based time-resolved detection and nanosecond fluorophores: the high quantum efficiency Ruthenium-dyes have bright far-red signals with low background due to time resolved detection, do not require strong UV excitation but rather can be excited with visible light, are chemically robust, and have proven and stable detection in many biological matrices. However, the instrumentation for proper and scalable implementation of Ruthenium Nano-TRF® had not previously been developed.
“We make the instruments that only existed as ideal specs in a team meeting or a protocol draft,” says Shawn M M Laymon, VP of Molecular Devices Global Services & Custom Solutions. “We look forward to a continued relationship with Roche and to building new relationships with customers looking for a partner to help them create custom detection and analysis systems that meet their specific workflow needs.”
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE